Movement Alert｜Hansoh Pharmaceutical Rises 3.07% in Regular Trading, Innovative Drug Pipeline Catalysts Continue Amid Sector Rebound-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Movement Alert｜Hansoh Pharmaceutical Rises 3.07% in Regular Trading, Innovative Drug Pipeline Catalysts Continue Amid Sector Rebound

Market Focus07-08 09:50

On July 8, Hansoh Pharmaceutical rose 3.07% in regular trading, trading at HKD 33.56/share, with turnover of HKD 97.03 million.

On the news front, the pharmaceutical sector rallied broadly, with CSPC Pharma up 1.65%, Hengrui Pharma up 3.02%, and Haixi Pharma up 2.90%, creating significant sector linkage. On July 2, the company announced that its self-developed Class 1 innovative drug HS-20136-2 injection received two clinical trial approval notices from NMPA for type 2 diabetes and weight management indications, extending pipeline catalysts.

Additionally, the companys weight-management drug olatorepatide injection NDA and HS-10568 injection NDA for secondary hyperparathyroidism in chronic kidney disease patients were both accepted by NMPA in early June, accelerating the commercialization of its innovative drug portfolio and sustaining positive market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1198016147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198016147","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharmaceutical Rises 3.07% in Regular Trading, Innovative Drug Pipeline Catalysts Continue Amid Sector Rebound","media":"Market Focus","content":"<p><p>On July 8, Hansoh Pharmaceutical rose 3.07% in regular trading, trading at HKD 33.56/share, with turnover of HKD 97.03 million.</p><p>On the news front, the pharmaceutical sector rallied broadly, with CSPC Pharma up 1.65%, Hengrui Pharma up 3.02%, and Haixi Pharma up 2.90%, creating significant sector linkage. On July 2, the company announced that its self-developed Class 1 innovative drug HS-20136-2 injection received two clinical trial approval notices from NMPA for type 2 diabetes and weight management indications, extending pipeline catalysts.</p><p>Additionally, the companys weight-management drug olatorepatide injection NDA and HS-10568 injection NDA for secondary hyperparathyroidism in chronic kidney disease patients were both accepted by NMPA in early June, accelerating the commercialization of its innovative drug portfolio and sustaining positive market sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharmaceutical Rises 3.07% in Regular Trading, Innovative Drug Pipeline Catalysts Continue Amid Sector Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharmaceutical Rises 3.07% in Regular Trading, Innovative Drug Pipeline Catalysts Continue Amid Sector Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-08 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 8, Hansoh Pharmaceutical rose 3.07% in regular trading, trading at HKD 33.56/share, with turnover of HKD 97.03 million.</p><p>On the news front, the pharmaceutical sector rallied broadly, with CSPC Pharma up 1.65%, Hengrui Pharma up 3.02%, and Haixi Pharma up 2.90%, creating significant sector linkage. On July 2, the company announced that its self-developed Class 1 innovative drug HS-20136-2 injection received two clinical trial approval notices from NMPA for type 2 diabetes and weight management indications, extending pipeline catalysts.</p><p>Additionally, the companys weight-management drug olatorepatide injection NDA and HS-10568 injection NDA for secondary hyperparathyroidism in chronic kidney disease patients were both accepted by NMPA in early June, accelerating the commercialization of its innovative drug portfolio and sustaining positive market sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1198016147","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198016147","pubTimestamp":1783475416,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 8, Hansoh Pharmaceutical rose 3.07% in regular trading, trading at HKD 33.56/share, with turnover of HKD 97.03 million.On the news front, the pharmaceutical sector rallied broadly, with CSPC...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"异动快讯|豪森药业常规交易涨3.07%板块反弹中创新药管线催化剂延续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On July 8, Hansoh Pharmaceutical rose 3.07% in regular trading, trading at HKD 33.56/share, with turnover of HKD 97.03 million.On the news front, the pharmaceutical sector rallied broadly, with CSPC Pharma up 1.65%, Hengrui Pharma up 3.02%, and Haixi Pharma up 2.90%, creating significant sector linkage. On July 2, the company announced that its self-developed Class 1 innovative drug HS-20136-2 injection received two clinical trial approval notices from NMPA for type 2 diabetes and weight management indications, extending pipeline catalysts.Additionally, the companys weight-management drug olatorepatide injection NDA and HS-10568 injection NDA for secondary hyperparathyroidism in chronic kidney disease patients were both accepted by NMPA in early June, accelerating the commercialization of its innovative drug portfolio and sustaining positive market sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}